002262.SHE Jiangsu Nhwa Pharmaceutical Co Ltd
- Market cap
- CNY 21.9B
- P/E
- 19.6x
- P/B
- 2.49x
- ROE
- 17.4%
- Dividend yield
- 1.67%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002262.SHE undervalued?
Graham number002262.SHE trades 47.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jiangsu Nhwa Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Jiangsu Nhwa Pharmaceutical Co Ltd yet.
Jiangsu Nhwa Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jiangsu Nhwa Pharmaceutical Co Ltd
Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin fumarate injection, alfentanil hydrochloride injection, oxycodone hydrochloride…
Full company profileJiangsu Nhwa Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jiangsu Nhwa Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.02B | 3.39B | 3.86B | 4.15B | 3.36B | 3.94B | 4.30B | 5.04B | 5.70B | 5.91B | 6.37B |
| Gross Profit | 1.38B | 1.61B | 2.14B | 2.59B | 2.52B | 3.00B | 3.26B | 3.64B | 4.15B | 4.26B | 4.56B |
| Operating Income | 354M | 446M | 610M | 771M | 856M | 926M | 1.00B | 1.18B | 1.34B | 1.16B | 1.74B |
| EBITDA | 393M | 455M | 646M | 776M | 878M | 960M | 1.02B | 1.20B | 1.36B | 1.37B | 1.74B |
| Net Income | 310M | 395M | 525M | 663M | 729M | 798M | 901M | 1.04B | 1.14B | 1.06B | 1.53B |
| EPS | 0.31 | 0.39 | 0.52 | 0.66 | 0.72 | 0.79 | 0.89 | 1.03 | 1.13 | 1.04 | 1.51 |
| Balance Sheet | |||||||||||
| Total Assets | 2.97B | 3.30B | 4.03B | 4.20B | 4.81B | 5.70B | 6.48B | 7.33B | 8.44B | 9.22B | 9.91B |
| Total Liabilities | 851M | 840M | 1.07B | 597M | 707M | 793M | 897M | 918M | 1.17B | 1.20B | 1.14B |
| Shareholders' Equity | 2.10B | 2.45B | 2.96B | 3.62B | 4.12B | 4.92B | 5.62B | 6.43B | 7.30B | 8.06B | 8.80B |
| Cash & Short-term Investments | 880M | 1.13B | 1.11B | 1.89B | 2.24B | 2.67B | 2.98B | 3.49B | 3.79B | 1.45B | 1.26B |
| Total Debt | 263M | 232M | 318M | 38.2M | 83.8M | 85.9M | 72.1M | 90.8M | 49.1M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 277M | 452M | 405M | 306M | 1.25B | 701M | 861M | 1.01B | 916M | 1.08B | - |
| Capital Expenditure | 102M | 166M | 171M | 160M | 269M | 206M | 328M | 374M | 450M | 437M | 380M |
| Free Cash Flow | 175M | 286M | 234M | 146M | 980M | 495M | 533M | 634M | 466M | 641M | 765M |
| Ratios | |||||||||||
| ROE | 14.8% | 16.1% | 17.7% | 18.3% | 17.7% | 16.2% | 16.0% | 16.1% | 15.7% | 13.1% | 17.4% |
| ROA | 10.4% | 12.0% | 13.0% | 15.8% | 15.1% | 14.0% | 13.9% | 14.1% | 13.5% | 11.5% | 15.4% |
| Net Profit Margin | 10.3% | 11.6% | 13.6% | 16.0% | 21.7% | 20.3% | 21.0% | 20.6% | 20.1% | 17.9% | 24.0% |
| Debt to Equity | 0.13x | 0.09x | 0.11x | 0.01x | 0.02x | 0.02x | 0.01x | 0.01x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jiangsu Nhwa Pharmaceutical Co Ltd dividends
- Dividend yield
- 1.67%
- Forward dividend
- 0.40 CNY
- Payout ratio
- 34.6%
- Ex-dividend date
- May 26, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 366M | 0.36 | 34.6% |
| 2024 | CNY 324M | 0.32 | 28.3% |
| 2023 | CNY 202M | 0.20 | 19.4% |
| 2022 | CNY 202M | 0.20 | 22.4% |
| 2021 | CNY 101M | 0.10 | 12.6% |
| 2020 | CNY 102M | 0.10 | 14.0% |
| 2019 | CNY 77.1M | 0.08 | 11.6% |
| 2018 | CNY 64.0M | 0.06 | 12.2% |
| 2017 | CNY 46.4M | 0.05 | 11.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 16:10 on May 12, 2017.
Who owns Jiangsu Nhwa Pharmaceutical Co Ltd
- Insiders 51.60%
- Institutions 11.03%
- Public & others 37.37%
- Shares outstanding 1.01B
- Free float 446M
Jiangsu Nhwa Pharmaceutical Co Ltd company profile
- Company name
- Jiangsu Nhwa Pharmaceutical Co Ltd
- Ticker
- 002262.SHE
- ISIN
- CNE100000CG8
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jul 23, 2008
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 6,003
- Fiscal year end
- December
- Address
- Enhua Technology Building, Xuzhou, China, 221009
- Phone
- 86 40 0900 2262
- Website
- nhwa-group.com
About Jiangsu Nhwa Pharmaceutical Co Ltd
Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin fumarate injection, alfentanil hydrochloride injection, oxycodone hydrochloride injection, olanzapine tablets, midazolam hydrochloride oral solution, clonazepam injection, lacosamide injection, micuronium injection, pregabalin capsules, vortioxetine hydrobromide tablets, tapentadone hydrochloride tablets, and oxycodone hydrochloride extended-release tablets. The company was founded in 1978 and is headquartered in Xuzhou, China.
Jiangsu Nhwa Pharmaceutical Co Ltd management
7- Mr. Jiaquan SunGM & Non-Independent Director · born 1976
- Mr. Gangsheng LiChief Financial Officer · born 1980
- Mr. Qing FuDeputy GM & Non-Independent Director · born 1961
- Mr. Zengliang ChenDeputy GM & Non-Independent Director · born 1963
- Mr. Ziliang YangDeputy GM & Non-Independent Director · born 1964
- Mr. Bao Zhou Duan CPADeputy GM & Secretary · born 1966
- Ji Rui HuAccounting Supervisor